May 5 witnessed the founding of the Chinese Intelligent Medicine Association of Chinese Medical Doctors Association (CMDA) in Beijing, with presence of LIU Wenxian, Deputy Director-general of the Planning and Information Department under National Health Commission of China; President ZHANG Yanling of Chinese Medical Doctors Association; YOU Zheng, Vice President and member of the Standing CPC Committee at Tsinghua University; Professor Lawrence, Vice President of Duke University in the United St

The award ceremony of “2017 Qingdao Annual Economic Accomplishment Award”, jointly organized by Qingdao Federation of Enterprises, Qingdao Association of Entrepreneurs, Qingdao Publishing Group, and Qingdao Radio and TV Station, was held in the 800 m2 broadcasting studio of Qingdao Radio and TV Station on May 5, 2018. With its excellent contribution and influence in the medical industry, BPG stood out of around 100 competing companies and became winner of the “2017 the Most Influential Company A

As a leading platform in China for innovation and integration of resources of the health industry, BPG provides optimized solutions for all segments of the massive health industrial chain through its Global Brand Ecosystem, Intelligent Application Ecosystem, Medical Service Ecosystem and Investment Ecosystem. In the recent two years, particularly, BAHEAL PHARMA has established a Health Industrial Park of over 1,000 Mu to push forward conversion of old to new kinetic energies; with AI as the poin

On January 9 - 14, the 2nd session of the 16th Qingdao People's Congress was held in the People's Hall of Qingdao. Shouldering the trust of the Qingdao people, the deputies to the Qingdao People's Congress from all walks of life in Qingdao attended the meeting to fulfill the sacred duties conferred by the Constitution and laws. As a deputy to the Qingdao People's Congress, President Fu Gang of the BAHEAL Pharmaceutical Group, centering on the spirit of the government work report, spoke glowingly

Qingdao Baheal Pharmaceutical Ltd. recently announced that, its advanced generics preparation technology has achieved major breakthrough, and Nida, an osmotic-controlled metformin-based diabetes medicine has been approved by FDA to come into the market, which will bring benefits to patients with type-2 diabetes, particularly, those patients accompanied with obesity and hyperinsulinemia.